technology commercialization

The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.

The firm said that the push toward outcomes-based medicine will drive innovation in diagnostic wearables and smart textiles over the next few years.

The funding will support manufacturing of the firm's Idylla PCR-based diagnostics platform and worker training at its Mechelen, Belgium facility.